11 Jul 2016 16:15
Collagen Solutions plc
("Collagen Solutions", the "Company" or the "Group")
11 July 2016
Director/PDMR Shareholding
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it was notified today that David Evans, Chairman of the Company, has today purchased a further 1,215,000 ordinary shares in the Company ("Ordinary Shares") at 8.0 pence per Ordinary Share.
Following this transaction, David Evans' total beneficial holding in the Company has increased to 16,003,730 Ordinary Shares representing 9.3 per cent. of the issued ordinary share capital of the Company.
Enquiries:
Collagen Solutions Plc |
| |||
Jamal Rushdy, CEO | Mob: +1 612 405 7709 | |||
Gill Black, CFO | Tel: 0141 648 9100 | |||
|
| |||
Panmure Gordon & Co (Nominated Adviser and Broker) |
| |||
Freddy Crossley, Duncan Monteith (Corporate Finance) | Tel: 020 7886 2500 | |||
Maisie Atkinson (Corporate Sales) | Tel: 020 7886 2905 | |||
|
| |||
Walbrook PR Ltd | Tel: 020 7933 8780 or collagen@walbrookpr.com | |||
Mike Wort | Mob: 07900 608 002 | |||
Anna Dunphy | Mob: 07876 741 001 | |||
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.